Literature DB >> 23269240

Reduced adult endothelial cell EphB4 function promotes venous remodeling.

Caroline C Jadlowiec1, Amanda Feigel, Chenzi Yang, Aaron J Feinstein, Susun T Kim, Michael J Collins, Yuka Kondo, Akihito Muto, Alan Dardik.   

Abstract

Reduced EphB4 expression is observed during vein graft adaptation and is associated with increased venous wall thickening. These findings suggest that EphB4 may mediate normal adult venous endothelial cell (EC) function and vein graft adaptation. We therefore tested the functional significance of EphB4 using EC with genetically reduced EphB4 signaling. EC were isolated from EphB4(+/+) and EphB4(+/-) mice. In vitro function was assessed through EC proliferation, migration, nitric oxide (NO) synthesis, and chemokine production. A mouse vein graft model was used to correlate in vitro findings with in vivo vein grafts. Smooth muscle cells (SMC) were subjected to proliferation and migration assays using EphB4(+/+) and EphB4(+/-) EC-conditioned medium. EphB4(+/-) EC exhibited diminished proliferation (P < 0.0001, n = 6), migration (P < 0.0001, n = 3), and NO production (P = 0.0012, n = 3). EphB4(+/-) EC had increased VEGF-A mRNA (P = 0.0006, n = 6) and protein (P = 0.0106, n = 3) as well as increased secretion of VEGF-A (P = 0.0010, n = 5), PDGF-BB (P < 0.0001, n = 6), and TGF-β1 (P < 0.0001, n = 6). EphB4(+/-)-conditioned medium promoted SMC proliferation (P < 0.0001, n = 7) and migration (P = 0.0358, n = 3). Vein grafts and EphB4(+/-) EC showed similarity with regard to VEGF-A and eNOS mRNA and protein expression. In conclusion, reduced venous EC EphB4 function is associated with a proangiogenic and mitogenic phenotype. EphB4(+/-) EC have increased secretion of SMC mitogens and reduced NO production that correlate with the thickened neointima formed during vein graft adaptation. These findings suggest that EphB4 remains active in adult venous EC and that loss of EphB4 plays a role in vein graft adaptation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269240      PMCID: PMC3625716          DOI: 10.1152/ajpcell.00333.2012

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  29 in total

1.  Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats.

Authors:  S Janssens; D Flaherty; Z Nong; O Varenne; N van Pelt; C Haustermans; P Zoldhelyi; R Gerard; D Collen
Journal:  Circulation       Date:  1998-04-07       Impact factor: 29.690

2.  Long-term results of in situ saphenous vein bypass. Analysis of 2058 cases.

Authors:  D M Shah; R C Darling; B B Chang; K M Fitzgerald; P S Paty; R P Leather
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

3.  Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium.

Authors:  R van der Zee; T Murohara; Z Luo; F Zollmann; J Passeri; C Lekutat; J M Isner
Journal:  Circulation       Date:  1997-02-18       Impact factor: 29.690

4.  Reduction of vein graft intimal hyperplasia and preservation of endothelium-dependent relaxation by topical vascular endothelial growth factor.

Authors:  Z Luo; T Asahara; Y Tsurumi; J M Isner; J F Symes
Journal:  J Vasc Surg       Date:  1998-01       Impact factor: 4.268

5.  Vascular endothelial growth factor expression in canine peripheral vein bypass grafts.

Authors:  A D Hamdan; L P Aiello; B D Misare; M A Contreras; G L King; F W LoGerfo; W C Quist
Journal:  J Vasc Surg       Date:  1997-07       Impact factor: 4.268

6.  Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis.

Authors:  R H Adams; G A Wilkinson; C Weiss; F Diella; N W Gale; U Deutsch; W Risau; R Klein
Journal:  Genes Dev       Date:  1999-02-01       Impact factor: 11.361

7.  Human venous endothelium can promote intimal hyperplasia in a paracrine manner.

Authors:  K E Allen; K Varty; L Jones; R D Sayers; P R Bell; N J London
Journal:  J Vasc Surg       Date:  1994-04       Impact factor: 4.268

8.  Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.

Authors:  H P Gerber; A McMurtrey; J Kowalski; M Yan; B A Keyt; V Dixit; N Ferrara
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

9.  Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits.

Authors:  A J Cayatte; J J Palacino; K Horten; R A Cohen
Journal:  Arterioscler Thromb       Date:  1994-05

10.  Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4.

Authors:  H U Wang; Z F Chen; D J Anderson
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

View more
  12 in total

1.  Ephrin type-B receptor 4 activation reduces neointimal hyperplasia in human saphenous vein in vitro.

Authors:  Daniel J Wong; Daniel Y Lu; Clinton D Protack; Go Kuwahara; Hualong Bai; Nirvana Sadaghianloo; George Tellides; Alan Dardik
Journal:  J Vasc Surg       Date:  2014-10-24       Impact factor: 4.268

Review 2.  Vein graft adaptation and fistula maturation in the arterial environment.

Authors:  Daniel Y Lu; Elizabeth Y Chen; Daniel J Wong; Kota Yamamoto; Clinton D Protack; Willis T Williams; Roland Assi; Michael R Hall; Nirvana Sadaghianloo; Alan Dardik
Journal:  J Surg Res       Date:  2014-01-30       Impact factor: 2.192

Review 3.  Membrane-mediated regulation of vascular identity.

Authors:  Takuya Hashimoto; Masayuki Tsuneki; Trenton R Foster; Jeans M Santana; Hualong Bai; Mo Wang; Haidi Hu; Jesse J Hanisch; Alan Dardik
Journal:  Birth Defects Res C Embryo Today       Date:  2016-03-17

4.  Eph-B4 mediates vein graft adaptation by regulation of endothelial nitric oxide synthase.

Authors:  Mo Wang; Michael J Collins; Trenton R Foster; Hualong Bai; Takuya Hashimoto; Jeans M Santana; Chang Shu; Alan Dardik
Journal:  J Vasc Surg       Date:  2016-01-24       Impact factor: 4.268

Review 5.  Improving the Outcome of Vein Grafts: Should Vascular Surgeons Turn Veins into Arteries?

Authors:  Toshihiko Isaji; Takuya Hashimoto; Kota Yamamoto; Jeans M Santana; Bogdan Yatsula; Haidi Hu; Hualong Bai; Guo Jianming; Tambudzai Kudze; Toshiya Nishibe; Alan Dardik
Journal:  Ann Vasc Dis       Date:  2017-03-31

6.  Eph-B4 regulates adaptive venous remodeling to improve arteriovenous fistula patency.

Authors:  Clinton D Protack; Trenton R Foster; Takuya Hashimoto; Kota Yamamoto; Monica Y Lee; Jan R Kraehling; Hualong Bai; Haidi Hu; Toshihiko Isaji; Jeans M Santana; Mo Wang; William C Sessa; Alan Dardik
Journal:  Sci Rep       Date:  2017-11-13       Impact factor: 4.379

7.  Inhibition of the Akt1-mTORC1 Axis Alters Venous Remodeling to Improve Arteriovenous Fistula Patency.

Authors:  Xiangjiang Guo; Arash Fereydooni; Toshihiko Isaji; Jolanta Gorecka; Shirley Liu; Haidi Hu; Shun Ono; Michelle Alozie; Shin Rong Lee; Ryosuke Taniguchi; Bogdan Yatsula; Naiem Nassiri; Lan Zhang; Alan Dardik
Journal:  Sci Rep       Date:  2019-07-30       Impact factor: 4.379

Review 8.  The critical role of the interplays of EphrinB2/EphB4 and VEGF in the induction of angiogenesis.

Authors:  Enming Du; Xue Li; Siyu He; Xiaohua Li; Shikun He
Journal:  Mol Biol Rep       Date:  2020-06-02       Impact factor: 2.316

9.  Arterial shear stress reduces eph-b4 expression in adult human veins.

Authors:  Lynn S Model; Michael R Hall; Daniel J Wong; Akihito Muto; Yuka Kondo; Kenneth R Ziegler; Amanda Feigel; Clay Quint; Laura Niklason; Alan Dardik
Journal:  Yale J Biol Med       Date:  2014-09-03

Review 10.  Ephs and Ephrins in Adult Endothelial Biology.

Authors:  Dianne Vreeken; Huayu Zhang; Anton Jan van Zonneveld; Janine M van Gils
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.